產(chǎn)品名稱(chēng)：BHK-21細(xì)胞,倉(cāng)鼠幼倉(cāng)鼠腎細(xì)胞

產(chǎn)品簡(jiǎn)介：上海博研生物*的ATCC細(xì)胞供應(yīng)商，提供BHK-21細(xì)胞,倉(cāng)鼠幼倉(cāng)鼠腎細(xì)胞的報(bào)價(jià)，咨詢(xún)，技術(shù)服務(wù)，咨詢(xún)選購(gòu)。
產(chǎn)品庫(kù)存：現(xiàn)貨
產(chǎn)品價(jià)格：詢(xún)價(jià)
供 應(yīng) 商：ATCC

描述：1961年3月，I.A. Macpherson和M.G.P. Stoker從1日齡的倉(cāng)鼠建立了BHK-21 (C-13)的親本。隨后84天連續(xù)培養(yǎng)，僅中斷8天進(jìn)行凍存，通過(guò)單細(xì)胞分離建立了13號(hào)克隆。這株細(xì)胞可用作轉(zhuǎn)染宿主，用于表達(dá)包含選擇及擴(kuò)增標(biāo)記的DNA(如Factor VIII,見(jiàn)ATCC CRL-8544)的載體。 在本庫(kù)通過(guò)支原體檢測(cè)。

動(dòng)物種別：倉(cāng)鼠

組織來(lái)源：正常腎

形態(tài)：成纖維細(xì)胞

培養(yǎng)基和添加劑：MEM培養(yǎng)基(GIBCO,貨號(hào)41500034，添加NaHCO3 1.5g/L，Sodium Pyruvate 0.11g/L)，90%；優(yōu)質(zhì)胎牛血清，10%。 氣相：空氣，95%；二氧化碳，5%。 溫度：37攝氏度。

技術(shù)相關(guān)問(wèn)答：
1. 如何選用特殊細(xì)胞系培養(yǎng)基？培養(yǎng)某一類(lèi)型細(xì)胞沒(méi)有固定的培養(yǎng)條件。在MEM中培養(yǎng)的細(xì)胞，很可能在DMEM或M199中同樣很容易生長(zhǎng)?？傊?MEM做粘附細(xì)胞培養(yǎng)、RPMI-1640做懸浮細(xì)胞培養(yǎng)是一個(gè)好的開(kāi)始。2. 何時(shí)須更換培養(yǎng)基？視細(xì)胞生長(zhǎng)密度而定， 或遵照細(xì)胞株基本數(shù)據(jù)上之更換時(shí)間，按時(shí)更換培養(yǎng)基即可。 3. 可否使用與原先培養(yǎng)條件不同之培養(yǎng)基？不能。每一細(xì)胞株均有其特定使用且已適應(yīng)之細(xì)胞培養(yǎng)基， 若驟然使用和原先提供之培養(yǎng)條件不同之培養(yǎng)基， 細(xì)胞大都無(wú)法立即適應(yīng)， 造成細(xì)胞無(wú)法存活。4.可否使用與原先培養(yǎng)條件不同之血清種類(lèi)？不能。血清是細(xì)胞培養(yǎng)上一個(gè)極為重要的營(yíng)養(yǎng)來(lái)源，所以血清的種類(lèi)和品質(zhì)對(duì)于細(xì)胞的生長(zhǎng)會(huì)產(chǎn)生*的影響。來(lái)自不同物種的血清， 在一些物質(zhì)或分子的量或內(nèi)容物上都有所不同，血清使用錯(cuò)誤常會(huì)造成細(xì)胞無(wú)法存活?；竟残?
1、所有的細(xì)胞表面均有由磷脂雙分子層與鑲嵌蛋白質(zhì)及糖被構(gòu)成的生物膜，即細(xì)胞膜。
2、所有的細(xì)胞都含有兩種核酸：即DNA與RNA。
3、作為遺傳信息復(fù)制與轉(zhuǎn)錄的載體。
4、作為蛋白質(zhì)合成的機(jī)器—核糖體，毫無(wú)例外地存在于一切細(xì)胞內(nèi)，核糖體，是蛋白質(zhì)合成的機(jī)器，在細(xì)胞遺傳信息流的傳遞中起重要作用。
5、所有細(xì)胞的增殖都以一分為二的方式進(jìn)行分裂。
6、能進(jìn)行自我增殖和遺傳
7、新陳代謝
8、細(xì)胞都具有運(yùn)動(dòng)性，包括細(xì)胞自身的運(yùn)動(dòng)和細(xì)胞內(nèi)部的物質(zhì)運(yùn)動(dòng)

相關(guān)產(chǎn)品：

人肝癌細(xì)胞，BEL-7402
人正常肝細(xì)胞，L-02（HL-7702)
人正常肝細(xì)胞，QSG-7701
人肝癌細(xì)胞，BEL-7404
人肝癌細(xì)胞，BEL-7405
人肝癌細(xì)胞，HuH-7
人肝癌細(xì)胞，Hep G2
人肝癌細(xì)胞，Hep 3B2.1-7
人肝癌細(xì)胞，Hep-3B
人肝癌細(xì)胞，HHCC
人肝癌細(xì)胞，HB611
人肝癌細(xì)胞，Homo Spaniens cell line Hep B1.2

REFERENCE：Gitschier J , et al. Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene. Nature 314: 738-740, 1985. PubMed: 2986011 Hutz MH , et al. Restriction site polymorphism in the phosphoglycerate kinase gene on the X chromosome. Hum. Genet. 66: 217-219, 1984. PubMed: 6325324 Macpherson I , Stoker M . Polyoma transformation of hamster cell clones--an investigation of genetic factors affecting cell competence. Virology 16: 147-151, 1962. PubMed: 14468055 Virology 14: 359-370, 1961. Macpherson I . Characteristics of a hamster cell clone transformed by polyoma virus. J. Natl. Cancer Inst. 30: 795-815, 1963. Deleersnyder V , et al. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 71: 697-704, 1997. PubMed: 8985401 Yang TT , et al. Quantification of gene expression with a secreted alkaline phosphatase reporter system. BioTechniques 23: 1110-1114, 1997. PubMed: 9421645 Hussain MA , et al. POU domain transcription factor brain 4 confers pancreatic alpha-cell-specific expression of the proglucagon gene through interaction with a novel proximal promoter G1 element. Mol. Cell. Biol. 17: 7186-7194, 1997. PubMed: 9372951 You M , et al. ch-IAp1, a member of the inhibitor-of-apoptosis protein family, is a mediator of the antiapoptotic activity of the v-Rel oncoprotein. Mol. Cell. Biol. 17: 7328-7341, 1997. PubMed: 9372964 Jelachich ML , Lipton HL . Theiler's murine encephalomyelitis virus kills restrictive but not permissive cells by apoptosis. J. Virol. 70: 6856-6861, 1996. PubMed: 8794327 Schnell MJ , et al. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J. Virol. 70: 2318-2323, 1996. PubMed: 8642658 Chang YE , et al. Properties of the protein encoded by the UL32 open reading frame of herpes simplex virus 1. J. Virol. 70: 3938-3946, 1996. PubMed: 8648731 Biological evaluation of medical devices. Part 5: Tests for in vitro cytotoxicity. Sydney, NSW, Australia: Standards Australia; Standards Australia AS ISO 10993.5-2002. Biological evaluation of medical devices--Part 5: Tests for in vitro cytotoxicity. Geneva (Switzerland): International Organization for Standardization/ANSI; ISO ISO 10993-5:1999. Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Centers for Disease Control (1993), Biosafety in Microbiological and Biomedical Laboratories Human Health Service Publication No. (CDC) 93-8395. U.S. Dept. of Health and Human Services; 3rd Edition U.S. Government Printing Office Washington D.C.